Evidence map›Paper›PMID 34204797›Full record

ArticleCancers2021

Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment.

Hsin-Pai Li, Chen-Yang Huang, Kar-Wai Lui, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Yung-Chia Kuo, Mei-Yuan Huang and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Hsin-Pai LiDepartment of Microbiology and Immunology, Chang Gung University, Taoyuan 33305, Taiwan.
Chen-Yang HuangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.ORCID 0000-0002-6767-0389
Kar-Wai LuiDepartment of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Yin-Kai ChaoDivision of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.ORCID 0000-0001-8649-8783
Chun-Nan YehLiver Research Center, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Li-Yu LeeDepartment of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Yenlin HuangDepartment of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Tung-Liang LinDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Yung-Chia KuoDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Mei-Yuan HuangDepartment of Microbiology and Immunology, Chang Gung University, Taoyuan 33305, Taiwan.
Yi-Ru LaiDepartment of Microbiology and Immunology, Chang Gung University, Taoyuan 33305, Taiwan.
Yuan-Ming YehGenomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
Hsien-Chi FanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
An-Chi LinDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Jason Chia-Hsun HsiehDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Kai-Ping ChangDepartment of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Chien-Yu LinDepartment of Radiation, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Hung-Ming WangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.ORCID 0000-0003-0066-829X
Yu-Sun ChangDepartment of Microbiology and Immunology, Chang Gung University, Taoyuan 33305, Taiwan.
Cheng-Lung HsuDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 33305, Taiwan.
Chang Gung University · TWChang Gung Memorial Hospital · TW

Funding

Chang Gung Memorial Hospital, Taiwan CMRPG3H0161~3, -3J0331~2, -3J0301~2, CORPG3J0161~2 C.-L. Hsu); (CMRPD1K0141~2, CMRPD1K0651, H.-P. LiMinistry of Education, Taiwan EMRPD1L0281, H.-P. LiMinistry of Science and Technology, Taiwan MOST107-2314-B-182-056-MY2, C.-L. Hsu); (MOST-108-2311-B-182-002, H.-P. Li
6 · The paper itself

Abstract

backgroundNasopharyngeal carcinoma (NPC) involves host genetics, environmental and viral factors. In clinical observations, patients of young and old ages were found to have higher recurrence and metastatic rates.

methodsCytokine array was employed to screen druggable target(s). The candidate target(s) were confirmed through patient-derived xenografts (PDXs) and a new EBV-positive cell line, NPC-B13.

resultsOverexpression of epithelial growth factor (EGF) and EGF receptor (EGFR) was detected in young patients than in older patients. The growth of NPC PDX tumors and cell lines was inhibited by EGFR inhibitors (EGFRi) cetuximab and afatinib when used separately or in combination with the cell cycle blocker palbociclib. Western blot analysis of these drug-treated PDXs demonstrated that the blockade of the EGF signaling pathway was associated with a decrease in the p-EGFR level and reduction in PDX tumor size. RNA sequencing results of PDX tumors elucidated that cell cycle-related pathways were suppressed in response to drug treatments. High EGFR expression (IHC score ≥ grade 3) was correlated with poor survival in metastatic patients (

conclusionsOur results provide encouraging preliminary data related to the combination treatment of EGFRi and palbociclib in patients with NPC.

Indexed as

CDK4/6 inhibitorEBVEGFEGFR blockerNPCNPC cell linePDXprecision medicineRNA sequencing

Identifiers

PMID34204797
PMCPMC8231497
OpenAlexW3169475240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.